Christopher Haqq, Chief Medical Officer at Atara Biotherapeutics, Inc. (ATRA), sold 1,604 shares at $19.95 ($32K) on 2016-11-15, disclosed to the SEC on 2016-11-17.
Scheduled sale ($32k) by Chief Medical Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| ATRA | SELL | 2019-02-08 | $956K | — | Filing → |
| ATRA | SELL | 2018-11-15 | $26K | — | Filing → |
| ATRA | SELL | 2018-09-27 | $582K | — | Filing → |